Castration-Resistant Prostate Cancer

Acronym

Definition

CRPC

Chartered Retirement Planning Counselor (College for Financial Planning)

CRPC

Castration-Resistant Prostate Cancer

CRPC

Center for Research on Parallel Computation (Rice University)

CRPC

Coral Ridge Presbyterian Church (Fort Lauderdale, Florida)

CrPC

Criminal Procedures Code

CRPC

Canadian Police Research Centre

CRPC

Central Resume Processing Center (US Army)

CRPC

Consumer Rights Protection Committee (Egypt)

CRPC

Cedar Rapids Photo Copy (Cedar Rapids, IA)

References in periodicals archive	?		Acronyms browser	?		Full browser	?
Author(s): Urban Emmenegger, MD (corresponding author) [1], Yoo-Joung Ko, MD, MMSc, SM, FRCPC [2] Docetaxel is the first-line cytotoxic treatment of choice for advanced castration-resistant prostate cancer (CRPC) resulting in improved palliation and a modest survival benefit compared to the former standard of care mitoxantrone, as demonstrated by two large randomized trials. PSA-based treatment response criteria in castration-resistant ... by Emmenegger, Urban; Ko, Yoo-Joung / Canadian Urological Association Journal (CUAJ) The open-label, multiple-dose study will examine the safety and effectiveness of TAK-700 in patients with chemotherapy-naove metastatic castration-resistant prostate cancer. Millennium Initiates Phase II Trial of Prostate Cancer Compound by Business Wire A second presentation ("Correlation of progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer who failed first-line chemotherapy: results from the SPARC trial," Halabi et al, Abstract #5150) evaluated whether PFS at three months was predictive of OS and explored the statistical dependencies between PFS and OS. New Data from Satraplatin Phase 3 Trial in Second-Line ... by Business Wire	CASSWG CASSY CAST CASTA CASTAC CASTAG CASTAR CASTASIA CASTAT CASTC CASTEL CASTER CASTF CASTFOREM CASTFOREM-DIS CASTI CASTIE CASTING CASTL CASTLE CASTME CASTNET CASTNO CASTO CASTOR Castration-Resistant Prostate Cancer CASTS CASTT CASTU CASTWG CASU CASU(F) CASUAL CASUL CASUP CASV CASV-MC-SCF CASVA CASVAC CASW CASWCM CASWI CASWO CASWS CASX CASY CASYS CASZ CAT CAT BACK CAT EXT	castrater castrates castrates castrati castrati castrating castrating castrating knife castrating knife castrating knife castrating knife castration castration castration castration anxiety castration anxiety castration anxiety castration complex castration complex castration complex castration complex castration complexes castration complexes Castration cult Castration cult Castration cult Castration fear Castration fear Castration fear Castration of Plants Castration-Resistant Prostate Cancer castration-responsive dermatosis castration-responsive dermatosis castration-responsive dermatosis castrations castrations castrations castrato castrato castrato Castrato singer Castrato singer castrator castrator castrators castrators castratos castratos Castratto Castratto Castrel Castren, Matthias Alexander Castrén, Matthias Alexander Castrensial Castrensian Castres Castres (Tarn) Castres Lameilhé Football Club Castres, Tarn Castries Castries

References in periodicals archive

Acronyms browser

Full browser

Author(s): Urban Emmenegger, MD (corresponding author) [1], Yoo-Joung Ko, MD, MMSc, SM, FRCPC [2] Docetaxel is the first-line cytotoxic treatment of choice for advanced castration-resistant prostate cancer (CRPC) resulting in improved palliation and a modest survival benefit compared to the former standard of care mitoxantrone, as demonstrated by two large randomized trials.

PSA-based treatment response criteria in castration-resistant ... by Emmenegger, Urban; Ko, Yoo-Joung / Canadian Urological Association Journal (CUAJ)

The open-label, multiple-dose study will examine the safety and effectiveness of TAK-700 in patients with chemotherapy-naove metastatic castration-resistant prostate cancer.

Millennium Initiates Phase II Trial of Prostate Cancer Compound by Business Wire

A second presentation ("Correlation of progression-free survival and overall survival in men with metastatic castration-resistant prostate cancer who failed first-line chemotherapy: results from the SPARC trial," Halabi et al, Abstract #5150) evaluated whether PFS at three months was predictive of OS and explored the statistical dependencies between PFS and OS.

New Data from Satraplatin Phase 3 Trial in Second-Line ... by Business Wire